221 related articles for article (PubMed ID: 34171085)
1. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
[TBL] [Abstract][Full Text] [Related]
2. Neonatal screening: identification of children with 11β-hydroxylase deficiency by second-tier testing.
Janzen N; Riepe FG; Peter M; Sander S; Steuerwald U; Korsch E; Krull F; Müller HL; Heger S; Brack C; Sander J
Horm Res Paediatr; 2012; 77(3):195-9. PubMed ID: 22508345
[TBL] [Abstract][Full Text] [Related]
3. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
[TBL] [Abstract][Full Text] [Related]
4. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China.
Zhan X; Han L; Qiu W; Gu X; Guo J; Chang S; Wang Y; Zhang H
Steroids; 2022 Sep; 185():109056. PubMed ID: 35660382
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
[TBL] [Abstract][Full Text] [Related]
6. Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia.
Tieh PY; Yee JK; Hicks RA; Mao CS; Lee WN
J Perinatol; 2017 Mar; 37(3):283-287. PubMed ID: 27929529
[TBL] [Abstract][Full Text] [Related]
7. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
[TBL] [Abstract][Full Text] [Related]
8. Determination of a steroid profile in heel prick blood using LC-MS/MS.
Boelen A; Ruiter AF; Claahsen-van der Grinten HL; Endert E; Ackermans MT
Bioanalysis; 2016; 8(5):375-84. PubMed ID: 26891684
[TBL] [Abstract][Full Text] [Related]
9. Birth Weight- or Gestational Age-adjusted Second-tier LCMSMS Cutoffs Improve Newborn Screening for CAH in New Zealand.
de Hora MR; Heather NL; Webster D; Albert BB; Hofman PL
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3390-e3399. PubMed ID: 34058748
[TBL] [Abstract][Full Text] [Related]
10. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia.
Sarafoglou K; Banks K; Gaviglio A; Hietala A; McCann M; Thomas W
Pediatrics; 2012 Nov; 130(5):e1261-8. PubMed ID: 23071209
[TBL] [Abstract][Full Text] [Related]
11. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
Fingerhut R
Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
[TBL] [Abstract][Full Text] [Related]
12. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency.
Kösel S; Burggraf S; Fingerhut R; Dörr HG; Roscher AA; Olgemöller B
Clin Chem; 2005 Feb; 51(2):298-304. PubMed ID: 15608154
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: Outcomes of Extended Pilot Study in 241,083 Infants.
Güran T; Tezel B; Çakır M; Akıncı A; Orbak Z; Keskin M; Selver Eklioğlu B; Ozon A; Özbek MN; Karagüzel G; Hatipoğlu N; Gürbüz F; Çizmecioğlu FM; Kara C; Şimşek E; Baş F; Aydın M; Darendeliler F
J Clin Res Pediatr Endocrinol; 2020 Sep; 12(3):287-294. PubMed ID: 32157855
[TBL] [Abstract][Full Text] [Related]
14. Twenty Years of Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: Role of Liquid Chromatography-Tandem Mass Spectrometry as a Second-Tier Test.
Cavarzere P; Camilot M; Palma L; Lauriola S; Gaudino R; Vincenzi M; Antoniazzi F; Teofoli F; Piacentini G
Horm Res Paediatr; 2022; 95(3):255-263. PubMed ID: 35350013
[TBL] [Abstract][Full Text] [Related]
15. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.
Allen DB; Hoffman GL; Fitzpatrick P; Laessig R; Maby S; Slyper A
J Pediatr; 1997 Jan; 130(1):128-33. PubMed ID: 9003862
[TBL] [Abstract][Full Text] [Related]
16. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
Kopacek C; de Castro SM; Prado MJ; da Silva CM; Beltrão LA; Spritzer PM
BMC Pediatr; 2017 Jan; 17(1):22. PubMed ID: 28095810
[TBL] [Abstract][Full Text] [Related]
17. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance.
Votava F; Novotna D; Kracmar P; Vinohradska H; Stahlova-Hrabincova E; Vrzalova Z; Neumann D; Malikova J; Lebl J; Matern D
Eur J Pediatr; 2012 Jun; 171(6):935-40. PubMed ID: 22234478
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening.
Monostori P; Szabó P; Marginean O; Bereczki C; Karg E
Horm Res Paediatr; 2015; 84(5):311-8. PubMed ID: 26397944
[TBL] [Abstract][Full Text] [Related]
19. Combined Gestational Age- and Birth Weight-Adjusted Cutoffs for Newborn Screening of Congenital Adrenal Hyperplasia.
Pode-Shakked N; Blau A; Pode-Shakked B; Tiosano D; Weintrob N; Eyal O; Zung A; Levy-Khademi F; Tenenbaum-Rakover Y; Zangen D; Gillis D; Pinhas-Hamiel O; Loewenthal N; de Vries L; Landau Z; Rachmiel M; Abu-Libdeh A; Eliakim A; Strich D; Koren I; German A; Sack J; Almashanu S
J Clin Endocrinol Metab; 2019 Aug; 104(8):3172-3180. PubMed ID: 30865229
[TBL] [Abstract][Full Text] [Related]
20. High frequency of non-classical congenital adrenal hyperplasia form among children with persistently elevated levels of 17-hydroxyprogesterone after newborn screening.
Castro PS; Rassi TO; Araujo RF; Pezzuti IL; Rodrigues AS; Bachega TASS; Silva IN
J Pediatr Endocrinol Metab; 2019 May; 32(5):499-504. PubMed ID: 31028712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
